Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharmacol Exp Ther ; 364(2): 287-299, 2018 02.
Article in English | MEDLINE | ID: mdl-29187590

ABSTRACT

Ischemia-reperfusion injury (IRI) is a common cause of acute kidney injury (AKI), which is an increasing problem in the clinic and has been associated with elevated rates of mortality. Therapies to treat AKI are currently not available, so identification of new targets that can be modulated to ameliorate renal damage upon diagnosis of AKI is essential. In this study, a novel cannabinoid receptor 2 (CB2) agonist, SMM-295 [3'-methyl-4-(2-(thiophen-2-yl)propan-2-yl)biphenyl-2,6-diol], was designed, synthesized, and tested in vitro and in silico. Molecular docking of SMM-295 into a CB2 active-state homology model showed that SMM-295 interacts well with key amino acids to stabilize the active state. In human embryonic kidney 293 cells, SMM-295 was capable of reducing cAMP production with 66-fold selectivity for CB2 versus cannabinoid receptor 1 and dose-dependently increased mitogen-activated protein kinase and Akt phosphorylation. In vivo testing of the CB2 agonist was performed using a mouse model of bilateral IRI, which is a common model to mimic human AKI, where SMM-295 was immediately administered upon reperfusion of the kidneys after the ischemia episode. Histologic damage assessment 48 hours after reperfusion demonstrated reduced tubular damage in the presence of SMM-295. This was consistent with reduced plasma markers of renal dysfunction (i.e., creatinine and neutrophil gelatinase-associated lipocalin) in SMM-295-treated mice. Mechanistically, kidneys treated with SMM-295 were shown to have elevated activation of Akt with reduced terminal deoxynucleotidyl transferase-mediated digoxigenin-deoxyuridine nick-end labeling (TUNEL)-positive cells compared with vehicle-treated kidneys after IRI. These data suggest that selective CB2 receptor activation could be a potential therapeutic target in the treatment of AKI.


Subject(s)
Biphenyl Compounds/pharmacology , Epithelial Cells/drug effects , Epithelial Cells/pathology , Kidney Tubules/drug effects , Kidney Tubules/pathology , Receptor, Cannabinoid, CB2/agonists , Reperfusion Injury/pathology , Thiophenes/pharmacology , Animals , Biphenyl Compounds/chemistry , Biphenyl Compounds/metabolism , Biphenyl Compounds/therapeutic use , Humans , Male , Mice , Mice, Inbred C57BL , Molecular Docking Simulation , Permeability , Protein Conformation , Receptor, Cannabinoid, CB2/chemistry , Receptor, Cannabinoid, CB2/metabolism , Reperfusion Injury/drug therapy , Solubility , Thiophenes/chemistry , Thiophenes/metabolism , Thiophenes/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...